Latest drug discovery Stories
“Proteomics: Technologies and Global Markets” is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) May 20, 2013 The main objective for the present report is to present the up-to-date market picture for proteomics into a single comprehensive report. The objective was to capture the changing industry dynamics and market shift occurring in this industry. Thus, it is timely to examine the key aspects of the proteomic industry. There is also an...
Selexis’ co-founder and scientific advisory board member will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression” Geneva, Switzerland (PRWEB) May 20, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that the Company’s co-founder will present data on the Company’s core technology at the 2013 Cell...
- IIMD China 2013 Hot Topics Preview SHANGHAI, May 17, 2013 /PRNewswire/ -- Medical devices are any medical items that are neither a drug nor a biological product. In light of their different mechanisms, actions and regulatory requirements, medical device (MD) trail evaluations are much more complicated than drug trails due to their unique clinical practices. Currently, the EMEA only evaluates MD safety instead of evaluating both safety and efficacy (which is left to the...
PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial has had no Severe Adverse Effect (SAE) reported. The Phase I open label clinical research...
REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York, NY. The presentation is scheduled for Wednesday, May 22,...
FARMINGTON, Conn., May 15, 2013 /PRNewswire-iReach/ -- World Pharma Congress is celebrating 12 years of preclinical research with its annual event covering the latest in drug targets, high-throughput screening, lead optimization, ADME and drug safety. Years of effectively covering the latest preclinical strategies and technologies that drive better predictions has culminated in priming this year's event to move further downstream into early formulations and drug delivery. (Photo:...
SAN DIEGO, May 15, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013. Brian M. Culley, Chief Executive Officer, said: "We have opened more than a dozen clinical sites in EPIC, our pivotal phase 3 study in sickle cell disease, and are on track to meet our goal of opening approximately 40 U.S. sites by year-end. We also plan to support U.S. enrollment by opening roughly 30 sites outside the U.S.,...
According to a new market report published by Transparency Market Research, "Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2013, the global computational biology market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from...
DOYLESTOWN, Pa., May 14, 2013 /PRNewswire/ -- Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced today that it has closed on $4.6 million in Series A financing led by two strategic investors. The Company intends to use the proceeds to accelerate pre-clinical development of its drug discovery pipeline of therapies for lysosomal storage diseases (LSDs), including lead candidates...
THE WOODLANDS, Texas, May 13, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 PM PDT (6:00 PM EDT) in Las Vegas, Nevada. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through...
